作者: Jeong, Lacey S ; Chandler, Selena ; Hakobyan, Tatevik ; Shockling, Lindsay ; Kimball, Kelly ; Hoff, Ellianna ; Chen, Yeong-Renn ; Kegecik, Karlina ; Srivastava, Geetika ; Kolz, Christopher ; Kang, Patrick T ; Pucci, Thomas ; Jabir, Abdur Rahman ; Dong, Feng ; Ohanyan, Vahagn ; Jia, Zhenyu ; Joshi, Hirva ; Shabani, Parisa ; Chilian, William M ; Chen, Chwen-Lih ; Sisakian, Hamayak ; Yin, Liya

AbstractBackground and aimsTakotsubo syndrome (TTS) is a conundrum without consensus about the cause. In a murine model of coronary microvascular dysfunction (CMD), abnormalities in myocardial perfusion played a key role in the development of TTS.Methods and resultsVascular Kv1.5 channels connect coronary blood flow to myocardial metabolism and their deletion mimics the phenotype of CMD. To determine if TTS is related to CMD, wild-type (WT), Kv1.5−/−, and TgKv1.5−/− (Kv1.5−/− with smooth muscle-specific expression Kv1.5 channels) mice were studied following transaortic constriction (TAC). Measurements of left ventricular (LV) fractional shortening (FS) in base and apex, and myocardial blood flow (MBF) were completed with standard and contrast echocardiography. Ribonucleic Acid deep sequencing was performed on LV apex and base from WT and Kv1.5−/− (control and TAC). Changes in gene expression were confirmed by real-time-polymerase chain reaction. MBF was increased with chromonar or by smooth muscle expression of Kv1.5 channels in the TgKv1.5−/−. TAC-induced systolic apical ballooning in Kv1.5−/−, shown as negative FS (P < 0.05 vs. base), which was not observed in WT, Kv1.5−/− with chromonar, or TgKv1.5−/−. Following TAC in Kv1.5−/−, MBF was lower in LV apex than in base. Increasing MBF with either chromonar or in TgKv1.5−/− normalized perfusion and function between LV apex and base (P = NS). Some genetic changes during TTS were reversed by chromonar, suggesting these were independent of TAC and more related to TTS.ConclusionAbnormalities in flow regulation between the LV apex and base cause TTS. When perfusion is normalized between the two regions, normal ventricular function is restored.

2001-09-01·American Journal of Physiology-Heart and Circulatory Physiology2区 · 医学

Effect of estrogen replacement therapy on distribution of myocardial blood flow in female anesthetized rabbits

2区 · 医学

Article

作者: Kingma, J. G. ; Rouleau, J. R. ; Blouin, A. ; Lavallée, B. ; Bélanger, A. ; Dagnault, A. ; Simard, D.

Estrogen replacement therapy reduces risk of cardiovascular events by altering coronary vasoregulation and distribution of blood flow. Vessel reactivity and blood flow distribution were assessed in anesthetized female rabbits in the following groups: 1) sham, 2) ovariectomy, 3) ovariectomy + 17β-estradiol, and 4) ovariectomy + dehydroepiandrosterone. After a 2-wk treatment, cardiac hemodynamics, vascular reserve, and blood flow were evaluated during the following infusions: 1) NaCl, or vehicle (0.5 ml/min), 2) acetylcholine (2 mg/kg), 3) isoproterenol (2 mg · kg−1 · min−1), and 4) chromonar (8 mg/kg). In hearts from ovariectomized rabbits, autoregulatory blood flow was preserved despite lower diastolic perfusion pressures (55 ± 8 vs. 64 ± 8 mmHg in sham) and rate-pressure product (14.4 ± 0.8 vs. 19.3 ± 0.8 beats/min · mmHg×10−3). Estrogen replacement therapy restored coronary pressure and reserve, and all drugs increased vascular conductance. In conclusion, in hearts from ovariectomized rabbits, vascular reserve declined because coronary pressure was lower; however, blood flow was preserved at a higher level than expected for oxygen demand. Estrogen replacement therapy restores myocardial oxygen supply-demand indices and returns coronary pressure-flow data to levels observed in animals with intact ovaries.

1996-02-19·FEBS Letters3区 · 生物学

Antioxidants differentially affect nuclear factor κB‐mediated nitric oxide synthase expression in vascular smooth muscle cells

3区 · 生物学

Article

作者: Markus Hecker ; Christiane Preiβ ; Rudi Busse ; Valérie B. Schini-Kerth

Increased ‘oxidative stress’ resulting in the activation of nuclear factor κB (NF‐κB) is thought to play a crucial role in the cytokine‐mediated expression of the inducible isoform of nitric oxide synthase (iNOS) in different cell types. Therefore, the effects of four different antioxidants, carbocromen, chrysin, 3,4‐dichloroisocoumarin (DCI) and N‐acetylserotonin (NAS), on iNOS expression were investigated in vascular smooth muscle cells (VSMC). All antioxidants strongly reduced the phorbol ester‐stimulated superoxide anion formation in native VSMC. Carbocromen (200 μM) and chrysin (50 μM) had no effect, while NAS (1 mM) abolished the increase in nitrine production and iNOS protein abundance in cultured VSMC exposed to interleukin‐1β (IL‐1β, 60 U/ml) or the adenylyl cyclase activator forskolin (10 μM). DCI also revealed a marked inhibitory effect in IL‐1β‐stimulated VSMC, but was less effective in cells treated with forskolin. DCI, but not NAS, also suppressed the activation of NF‐κB in VSMC exposed to IL‐1β, while no significant NF‐κB activation was detected in forskolin‐treated cells. These findings demonstrate that antioxidants differentially affect iNOS expression in VSMC both at the transcriptional level by preventing the activation of NF‐κB and at the post‐transcriptional level, presumably by promoting iNOS mRNA or protein degradation. They also suggest that reactive oxygen intermediates do not play a role in the activation of NF‐κB by IL‐1β in VSMC, and that transcripton factors other than NF‐κB mediate the induction of iNOS expression by elevating the intracellular concentration of cyclic AMP.

项与盐酸卡波罗孟相关的新闻（医药）

2024-07-20

·米内网

【瞩目】暴涨283%独家中成药，东北药企申请保护

精彩内容近日，国家药监局官网显示，愈心痛胶囊申请中药品种保护获受理。该药是大连胜光药业的独家品种，用于气虚血瘀证的劳累型冠心病心绞痛。米内网数据显示，2023年中国三大终端六大市场心血管疾病中成药销售规模超过500亿元。来源：NMPA官网愈心痛胶囊为大连胜光药业的独家中成药，是国家医保药品目录乙类品种。该药主要由延胡索、红参、三七等组成，具有益气活血、通脉止痛的功效，用于气虚血瘀证的劳累型冠心病心绞痛患者，症见胸部刺痛或绞痛，痛有定处，胸闷气短，倦怠乏力等。米内网数据显示，2023年中国三大终端六大市场（统计范围详见本文末）心血管疾病中成药销售额超过500亿元，同比增长4.76%。其中，愈心痛胶囊销售额增幅达283.24%，从细分终端上看，公立医院终端（城市公立医院+县级公立医院）为其主要销售渠道，占据超77%的市场份额。近年来中国三大终端六大市场愈心痛胶囊销售趋势（单位：万元）来源：米内网格局数据库大连胜光药业创立于2002年，其前身为吉林敖东集团大连药业，是一家集药品研发、‌生产、‌销售于一体的现代化综合制药企业。公司以制药为主导产业，‌聚焦中药、‌西药、‌外用药等创新产品开发，目前已有21款产品获批上市，包括治疗脑络瘀阻的血塞通分散片、用于镇静助眠的谷维素片、以及女性外用短效避孕药壬苯醇醚膜等。大连胜光药业已获批上市的产品来源：米内网中国上市药品（MID）数据库21个获批上市的产品中，化学药及中成药分别占15个和6个席位，其中有5个为医保目录甲类药、8个为医保目录乙类药；按治疗大类统计，神经系统化学药、心脑血管系统化学药、全身用抗感染化学药及生殖泌尿系统和性激素类化学药占据主导，各有3个产品在列；OTC分类上看，甲类（含双跨）产品合计有7个。资料来源：米内网数据库、NMPA官网注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至7月19日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 ●温馨提示● 因为微信公众号修改了推送规则，最近很多读者反映没有及时看到推文。把米内网设为“星标”，就能每天与我们不见不散啦，具体操作如下：【分享、点赞、在看】点一点不失联哦

上市批准

100 项与盐酸卡波罗孟相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	盐酸卡波罗孟	C01DX05	DB13279

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
心绞痛	中国	锦州九泰药业有限责任公司	1996-01-01
心律失常	中国	锦州九泰药业有限责任公司	1996-01-01
冠状动脉疾病	中国	锦州九泰药业有限责任公司	1996-01-01
心肌梗塞	中国	锦州九泰药业有限责任公司	1996-01-01